At its June 16, 2022, meeting in Amsterdam, the European Medicines Agency's (EMA) management board, among other items, heard an update about the implementation of the new EU regulation that reinforces EMA’s role in crisis preparedness and management for medicinal products and medical devices.
The newly-established Medicines Shortages Steering Group (MSSG) had its first meeting on May 11 and is now fully operational. It has been put in place to mitigate and respond to medicine supply issues caused by major events or public health emergencies. The Emergency Task Force (ETF), which was originally convened in March 2020 to specifically address the COVID-19 pandemic, started operating under the new rules in mid-April. The board adopted the rules of procedure via written procedure of both entities in April.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze